Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | June 2009 |
| End Date: | January 2011 |
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in
combination with pegylated interferon alpha and ribavirin, are safe and demonstrate
sufficient anti-hepatitis C virus activity.
combination with pegylated interferon alpha and ribavirin, are safe and demonstrate
sufficient anti-hepatitis C virus activity.
Key Inclusion Criteria:
- Patients chronically infected with hepatitis C virus (HCV) genotype 1
- HCV RNA viral load of ≥10*5* IU/mL (100,000 IU/mL) at screening
- Treatment naive
Key Exclusion Criteria:
- Women of child-bearing potential
- Cirrhosis
- Coinfection with HIV or hepatitis B virus
We found this trial at
12
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials